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Abstract
Thyroid hormones are required for skeletal development and establishment of peak bone mass. Hypothyroidism in children results in
growth retardation with delayed skeletal development, whereas thyrotoxicosis accelerates bone maturation. In adults, T3 regulates bone
turnover and bone mineral density, and normal euthyroid status is essential to maintain optimal bone strength. Population studies indica-
te that hypothyroidism and hyperthyroidism are both associated with an increased risk of fracture. Nevertheless, the mechanism of T3
action in bone is incompletely understood. Studies in mutant mice have demonstrated that T3 action in bone is mediated principally by T3
receptor a (TRa). T3 exerts anabolic actions during growth to stimulate peak bone mass acrrual, but has catabolic effects on the adult
skeleton that increase bone turnover. Recent studies have also suggested that TSH may have direct actions in bone cells, but such effects
are difficult to resolve in vivo because thyroid hormone and TSH concentrations are maintained in an inverse relationship by the hypotha-
lamic-pituitary-thyroid axis. Current understanding is based on studies in mice that harbor germline mutations in the genes encoding
TRa, TRb or the TSH receptor and it is not clear whether the skeletal effects of these mutations result from disruption of primary T3 actions
in bone cells or whether they are secondary to systemic effects on other endocrine pathways that regulate skeletal development and bone
mass. Tissue-specific disruption of thyroid hormone signalling in bone cells will be required to address this issue. Such studies are likely to
identify key components of the T3 signalling pathway that may represent suitable drug targets for treatment of osteoporosis.
(Pol J Endocrinol 2009; 60 (5): 380–388)
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Streszczenie
Hormony tarczycy są niezbędne dla prawidłowego rozwoju układu kostnego i uzyskania szczytowej masy kostnej. Niedoczynność tar-
czycy u dzieci prowadzi do ograniczenia (opóźnienia) tempa wzrostu spowodowanego opóźnieniem rozwoju kości, podczas gdy nad-
czynność tarczycy przyspiesza dojrzewanie układu kostnego. U dorosłych hormony tarczycy regulują obrót kostny i gęstość mineralną
układu kostnego. Stan eutyreozy jest więc istotny dla utrzymania optymalnej jakości układu kostnego. Wyniki badań populacyjnych
wykazały, że zarówno niedoczynność, jak i nadczynność tarczycy są związane ze zwiększonym ryzykiem złamań kości. Mimo to mecha-
nizm działania trijodotyroniny (T3) w kości nie jest do końca poznany. W badaniach zmutowanych myszy wykazano, że działanie T3 na
kość zachodzi poprzez interakcje hormonu z receptorem a (TRa). W okresie młodości i wzrastania T3 wywiera na kość efekt anaboliczny
i odpowiada za szczytowy przyrost kości. W późniejszym okresie życia T3 wywiera efekt kataboliczny, zwiększając resorpcję wapna
i obrót kostny. W ostatnim okresie wyniki niektórych badań mogą wskazywać, że TSH ma bezpośredni wpływ na komórki kości, ale
problem ten jest bardzo trudny do ostatecznego ustalenia w warunkach in vivo, wobec tego, że stężenie TSH i hormonu tarczycy jest
utrzymywane w odwrotnym wzajemnym stosunku (sprzężeniu zwrotnym) przez układ podwzgórze–przysadka–tarczyca. Obecna wie-
dza w tym zakresie wynika z doświadczeń myszami, u których zmutowano geny kodujące TRa, TRb i receptor TSH. Jednak nie można
kategorycznie ustalić, czy wpływ tych mutacji na szkielet zależy od zmienionej ekspresji T3 w komórkach kośćca, czy jest następstwem
tych mutacji na czynność innych układów endokrynnych, które regulują rozwój szkieletu i masę kostną. Blokowanie sygnału od hormo-
nu tarczycy w poszczególnych tkankach i układach będzie konieczne, aby rozwiązać te niejasności. Przeprowadzenie takich badań po-
zwoli zidentyfikować kluczowe mechanizmy działania T3 na komórki kości i określić nowe cele w leczeniu osteoporozy.
(Endokrynol Pol 2009; 60 (5): 380–388)
Słowa kluczowe: hormony tarczycy, T3, T4, obrót kostny, osteoporoza
Effects of thyroid hormones
on the skeleton in humans
Development and growth
Thyroid hormones exert a critical influence on the de-
velopment of the skeleton. Thyroid hormone deficien-
cy in children results in retarded skeletal development,
delayed bone age, and growth arrest accompanied by
epiphyseal dysgenesis [1, 2]. By contrast, in childhood
thyrotoxicosis there is accelerated skeletal development
and growth with advanced bone age. However, short
stature may ultimately occur despite advanced skeletal
maturation because of premature fusion of the epiphy-
seal growth plates, leading to early cessation of growth.
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In severe cases, craniosynostosis may occur due to pre-
mature closure of the sutures of the skull [3]. Resistan-
ce to thyroid hormone is an autosomal dominant con-
dition resulting from dominant negative mutations of
the thyroid hormone receptor TRb. The clinical featu-
res of RTH are variable because the functional proper-
ties of mutant TRb proteins differ according to the spe-
cific mutation and according to other genetic modify-
ing factors that are currently unknown [4]. Accordin-
gly, diverse skeletal abnormalities have been described
in RTH, including short stature, osteoporosis, increased
bone density, and various craniofacial and other skele-
tal malformations [4–6]. The reasons for such diversity
are unknown but no prospective analysis has been per-
formed in a series of patients with RTH. Available in-
formation is largely derived from case reports and may
be confounded by treatment of patients by thyroidec-
tomy or anti-thyroid drugs that could influence skele-
tal development.
In summary, clinical evidence from children with
hypothyroidism, thyrotoxicosis, or RTH indicates that
thyroid hormones are essential for bone development.
Thyroid hormone deficiency results in developmental
delay, whereas thyroid hormone excess accelerates bone
formation and growth. Thus, euthyroid status during
childhood is essential for normal linear growth and to
establish peak bone mass in early adulthood [1].
Bone maintenance
In the adult skeleton, thyroid hormones act as home-
ostatic regulators that maintain bone mass. In hypothy-
roidism there is reduced bone turnover affecting both
bone resorption and bone formation, and the prolon-
ged bone formation phase leads to an increased mine-
ralization phase [7]. Recent population studies have
shown that hypothyroidism is associated with an in-
creased risk of fracture, although the underlying me-
chanisms resulting in this association are unclear
[8–10]. In both pre-menopausal and post-menopausal
women and in men, thyrotoxicosis is an established risk
factor for osteoporosis [11]. Osteoporosis in thyrotoxi-
cosis results from high bone turnover, with dispropor-
tionate increases in bone resorption and bone forma-
tion that lead to a loss of approximately 10% of bone
mass per remodelling cycle [12]. The accelerated bone
loss in established thyrotoxicosis results in low bone
mineral density and an increased risk of fracture. Re-
cent studies have investigated whether endogenous
subclinical hyperthyroidism (suppressed TSH in the
presence of normal circulating T3 and T4 levels) or exces-
sive thyroid hormone replacement leading to TSH sup-
pression are associated with reduced bone mineral den-
sity and fracture. These studies have produced conflic-
ting results but have been confounded by differences
in study design, the inclusion of heterogeneous groups
of patients, small numbers of patients, and a lack of cle-
ar prospective data [11]. Population studies, however,
suggest that subclinical hyperthyroidism may be asso-
ciated with an increased risk of fracture at the hip and
lumbar spine in post-menopausal women [13, 14].
In summary, clinical studies indicate that euthyroid
status in adults is essential for normal bone turnover
and mineralization and to maintain optimal bone
strength [11, 15, 16].
The structure of the skeleton is established during
development and growth and determined initially by
the acquisition of peak bone mass. Thereafter, skeletal
integrity is maintained by the dynamic process of bone
turnover (Fig. 1), which continues throughout life and
determines the rate of bone loss during adulthood [17].
Thus, bone strength and fracture risk are primarily de-
termined by peak bone mass acquired during growth
and the rate of bone loss in adulthood. Euthyroid sta-
tus is essential for optimal bone mineral deposition du-
ring growth, and thyroid hormones regulate the rates
of bone resorption and formation, thereby maintaining
homeostatic regulation of bone turnover and bone loss
during adulthood [1, 11, 18]. Thus, the set-point of the
hypothalamic-pituitary-thyroid (HPT) axis, which de-
fines normal euthyroid status within an individual [19,
20], is a key homeostatic regulator of skeletal integrity
throughout life that may ultimately determine fracture
risk.
Human genetics
In healthy individuals, free T3, free T4, and TSH levels
fluctuate over a range that is less than 50% of the nor-
mal reference range [20]. This variation in thyroid sta-
tus within an individual is narrower than the broad in-
ter-individual variation seen in the population. Each
person has a unique HPT axis set-point that lies within
the population reference range, indicating that there is
variation in tissue sensitivity to thyroid hormones be-
tween normal individuals [19]. Data from the UK Adult
Twin Registry estimate the heritability for free T3 con-
centration at 23%, free T4 at 39%, and TSH at 65%, whilst
estimates from a Danish twin study were 64%, 65%, and
64%, respectively [21, 22]. A genome wide screen iden-
tified eight quantitative trait loci linked to circulating
fT3, fT4, and TSH levels, indicating that thyroid status is
inherited as a complex genetic trait [23]. Similarly, unbia-
sed genome wide association studies and candidate
gene approaches have shown that osteoporosis is
a polygenic disorder in which many genes and signal-
ling pathways exert small contributions that influence
bone size, BMD, and fracture susceptibility [24].
382
Actions of thyroid hormones in bone Graham R. Williams
PR
A
C
E 
PO
G
LĄ
D
O
W
E
These observations raise the possibility that varia-
tions in bone turnover, BMD, and fracture susceptibili-
ty in normal individuals may be associated with diffe-
rences in their HPT axis set-points. Furthermore, genes
that establish the HPT axis set-point and thus regulate
thyroid status may also influence the acquisition of peak
bone mass, skeletal growth, and bone turnover and the-
reby contribute to the genetic determination of fractu-
re risk. This hypothesis is consistent with observations
in other physiological complex traits including BMI,
blood pressure, heart rate, atherosclerosis, serum cho-
lesterol, and psychological well-being, in which varia-
tions have been associated with small alterations in thy-
roid function and with polymorphisms in thyroid pa-
thway genes that are themselves associated with alte-
red serum thyroid hormone and TSH concentrations
[25]. These new developments in our understanding the
physiological regulation of the HPT axis and thyroid
hormone action in target tissues have been extended
recently to investigation of the skeleton, and these stu-
dies suggest common genetic factors may be involved
in the determination of thyroid status, bone turnover,
and BMD [26, 27].
Future prospective studies investigating the relation-
ships between variations in the HPT axis set-point and
genes regulating thyroid hormone transport, metabo-
lism and action with bone mass and fracture risk will
need to be well designed and adequately powered.
Stringent exclusion criteria will be required to define
large populations of individuals that can be followed
up prospectively for prolonged periods. Nevertheless,
such studies have the potential to individualise fractu-
re risk prediction and inform the choice of preventati-
ve therapy [25].
Figure 1. The bone remodelling cycle. The continual process of bone remodelling is essential for
maintenance of bone mass and micro-architecture. Bone remodelling involves osteocytes, osteoclasts,
and osteoblasts. Osteocytes form from osteoblasts that have become embedded within mineralized bone.
When local skeletal micro-damage occurs or when there is a reduction in mechanical loading, osteocytes
respond either by releasing cytokines and chemo-attractants or by undergoing apoptosis. These responses
result in local recruitment of osteoclast precursor cells and cause mature osteoclasts to initiate bone
resorption. Osteoclasts excavate a resorption cavity over a period of 3–5 weeks until this process is
followed by recruitment of osteoblasts. Osteoblasts secrete and mineralize osteoid to replace the resorbed
bone over a period of approximately three months. Coupling of osteoclast and osteoblast activities via
signalling between the two cell lineages regulates the bone remodelling cycle and results in skeletal
homeostasis with preservation of bone strength
Rycina 1. Cykl przebudowy kości. Ciągły proces przebudowy kości jest niezbędny do zachowania
masy kostnej i prawidłowej mikroarchitektury. W tym procesie uczestniczą osteocyty, osteoklasty
i osteoblasty. Osteocyty przekształcają się z osteoblastów, które zostały otoczone zmineralizowaną tkanką
kostną. Gdy powstają mikrouszkodzenia szkieletu lub następuje zmniejszenie mechanicznego obciążenia
kości, osteocyty uwalniają cytokiny i substancje chemotaktyczne lub ulegają apoptozie. Reakcja
osteocytów powoduje miejscową rekrutację prekursorów osteoklastów i stymuluje dojrzałe osteoklasty
do resorpcji kości. Osteoklasty drążą jamkę resorpcyjną przez okres 3–5 tygodni, po czym następuje
rekrutacja osteoblastów. Rolą tych komórek jest produkcja i mineralizacja osteoidu, który zastępuje
kość usuniętą przez osteoklasty w ciągu około 3 miesięcy. Sprzężenie aktywności osteoklastów
i osteoblastów poprzez przekazywanie sygnałów między tymi dwiema liniami komórkowymi reguluje
cykl przebudowy kości i zapewnia homeostazę tkanki kostnej i zachowanie wytrzymałości kości
Bone resorption
Paracrine communication between
osteoblasts and osteoclasts
Osteoid
Bone
Bone formation
Pre-osteoclasts
Activated osteoclasts
Lining cells
Osteoblasts
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Mechanism of thyroid hormone action
Circulating thyroid hormone levels are maintained in
the euthyroid range by a negative feedback loop. Thy-
rotropin releasing hormone (TRH) is synthesized in the
hypothalamus and stimulates synthesis and secretion
of TSH from the anterior pituitary gland. TSH stimula-
tes growth of thyroid follicular cells and the synthesis
and release of thyroid hormones. Thyroid hormones act
via thyroid hormone receptors (TRs) in the hypothala-
mus and pituitary to inhibit TRH and TSH synthesis and
secretion. This negative feedback loop maintains circu-
lating thyroid hormones and TSH in an inverse relation-
ship that defines the HPT axis set-point [1].
The thyroid gland secretes the pro-hormone thyro-
xine (T4) and a small amount of physiologically active
3,5,3'-L-triiodothyronine (T3). The majority of circula-
ting T3 is generated by 5’-deiodination of T4 in liver and
kidney by the type 1 iodothyronine deiodinase enzy-
me (D1). Circulating free T4 levels are maintained at
3-4-fold higher concentrations than free T3. Intra-cellular
availability (Fig. 2) of T4 and T3 is determined by active
uptake of the free hormones by specific cell membrane
transporters including monocarboxylate transporter-8
(MCT8), MCT10, and organic acid transporter protein-
1c1 (OATP1c1) [28]. Availability of the active hormone
T3 to the nuclear TRs is subsequently controlled by acti-
vities of the type 2 and 3 deiodinase enzymes (D2 and
D3). D2 converts T4 to T3 by catalyzing removal of
a 5'-iodine atom, whilst D3 prevents activation of T4 and
inactivates T3 by removal of a 5-iodine atom to genera-
te the metabolites 3,3',5'-L-triiodothyronine (reverse T3)
and 3,3'-diiodothyronine (T2), respectively. The relati-
ve levels of D2 and D3 therefore regulate the intra-nuc-
lear concentration of T3 [29]. The THRA and THRB ge-
nes encode three functional TRs: TRa1, TRb1, and TRb2,
which act as hormone inducible transcription factors
that regulate expression of T3-responsive target genes
[30]. TRa1 and TRb1 are expressed widely, but their re-
lative concentrations differ during development and in
adulthood due to tissue-specific and temporo-spatial
regulation [31]. Expression of TRb2, however, is restric-
ted. In the hypothalamus and pituitary, it controls the
HPT axis feedback loop by mediating the inhibitory
actions of thyroid hormones on TRH and TSH expres-
sion [32, 33].
Thyroid hormone action in bone
In the skeleton, TRa1 and TRb1 are expressed in growth
plate chondrocytes, bone marrow stromal cells, and
bone-forming osteoblasts, but it is not certain whether
they are present in bone-resorbing osteoclasts [18,
34–36]. In the growth plate, T3 inhibits cell proliferation
and stimulates differentiation of hypertrophic chondro-
cytes to regulate endochondral ossification and linear
growth [35]. These regulatory effects of T3 on the rate
of growth plate chondrocyte differentiation occur via
Figure 2. Mechanism of thyroid hormone action. Levels of
circulating free T4 in serum are 3–4-fold higher than free T3. T4
and T3 enter target cells by active uptake mediated by cell membrane
transporters (MCT8). T3 availability to its nuclear receptors, TRa
and TRb, is controlled by the relative activities of the type 2 and 3
deiodinases (D2 and D3). D2 activates T4 by converting it to T3,
whereas D3 inactivates both T4 and T3. Once inside the nucleus,
T3 binds TRa or TRb. The hormone bound receptor interacts with
retinoid X receptor (RXR) and the TR/RXR heterodimer complex
interacts with thyroid hormone response element sequences (TRE)
located in the promoter regions of T3-regulated target genes to
control their expression in a hormone-dependent manner
Rycina 2. Mechanizm działania hormonów tarczycy. Stężenie
krążącej wolnej T4 w surowicy jest 3–4-krotnie wyższe niż wolnej
T3. Zarówno T4, jak i T3 dostają się do komórek poprzez mecha-
nizm aktywnego wychwytu, w którym pośredniczą transportery
błonowe (MCT8). Dostępność T3 dla jej receptorów jądrowych,
TRa i TRb, zależy od względnej aktywności dejodynazy 2 i 3 (D2
i D3). Dejodynaza 2 aktywuje T4 poprzez przekształcenie jej do
T3, natomiast D3 inaktywuje zarówno T4, jak i T3. Po wniknięciu
do jądra komórkowego T3 wiąże się z TRα lub TRb. Receptor zwią-
zany z hormonem wchodzi w interakcję z receptorem retinoido-
wym (RXR), a następnie heterodimer TR/RXR oddziałuje z
regulatorową sekwencją odpowiedzi na hormony tarczycy (TRE,
thyroid hormone response) zlokalizowaną w regionie promo-
torowym odpowiednich genów regulatorowych i wpływa na ich
ekspresję w zależności od stężenia hormonów
T4
T4 T4
T4T3
T4
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T4 T3
Ligand
activation
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T3
Ligand
inactivation
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TRa1 and involve interactions with key signalling pa-
thways that control chondrocyte differentiation, inclu-
ding the Indian hedgehog/parathyroid hormone-rela-
ted peptide feedback loop and the growth hormone/
/insulin-like growth factor-1 (GH/IGF-1) and fibroblast
growth factor receptor-3 (FGFR3) signalling pathways
[37, 38]. Studies of bone marrow stromal cells indicate
that T3 acts via complex cytokine and growth factor si-
gnalling pathways, which are known to regulate com-
munication between osteoblast and osteoclast cell line-
ages within the bone marrow microenvironment. T3 also
regulates osteoblast differentiation and function via
TRa1 and by interacting with FGFR1 signalling [39]. The
predominant consequences of hypothyroidism and
hyperthyroidism on the skeleton, however, result from
effects on osteoclast activity and bone resorption. De-
spite this, it is not clear whether T3 exerts direct actions
in osteoclasts or whether the effects on bone resorption
result from secondary responses of osteoclasts to the
actions of T3 in chondrocytes, bone marrow stromal cells,
or osteoblasts. An important challenge in the future will
be to characterize the cellular actions of thyroid hor-
mones in bone in detail
Thyroid hormone receptor regulation
of the HPT axis and the skeleton
Studies of the relative levels of expression of TRs in va-
rious tissues have shown that TRb expression predo-
minates in hypothalamus and pituitary [31–33, 40] (Fig. 3).
Accordingly, and in keeping with the causative role
for dominant-negative mutations of TRb in the human
syndrome of RTH [4], detailed analyses of transgenic
and TR knockout mice have revealed that TRb regula-
tes the sensitivity of the hypothalamus and pituitary to
negative feedback inhibition by thyroid hormones [41].
These studies demonstrate that TRb controls the HPT
axis set-point thereby determining the levels of circula-
ting thyroid hormones. By contrast, TRa is expressed
at substantially higher levels than TRb in bone, sugge-
sting the skeleton may be a predominantly TRa-respon-
sive T3 target tissue. These findings suggested that mu-
tation or deletion of the THRA and THRB genes would
have differing consequences to the skeleton and wo-
uld be informative in elucidating the physiological re-
lationship between the central and peripheral actions
of thyroid hormones [42, 43] (Fig. 4).
TSH receptor expression in bone
Investigation of the relationship between thyroid hor-
mone actions centrally and in bone was complicated,
however, by the finding that osteoblasts and osteocla-
sts express the TSH receptor (TSHR) [44]. Analysis of
congenitally hypothyroid TSHR knockout mice treated
with thyroid extract revealed a phenotype of high bone
turnover osteoporosis in animals at approximately
6–7 weeks of age. Because of these findings, TSH was
proposed as a negative regulator of bone turnover, and
it was suggested that bone loss in TSHR knockout mice
was a direct consequence of TSH deficiency. Although
this raises important and provocative questions regar-
ding the precise role of the HPT axis in skeletal home-
ostasis, the findings in TSHR knockout mice are confo-
unded because these mice require thyroid hormone
supplementation for survival after weaning at 3–4 we-
eks of age [45]. In mice, T4 and T3 levels rise rapidly to
reach their physiological peak at 2 weeks of age, and
growth velocity is maximal at this time. Since TSHR
knockout mice were supplemented with thyroid extract
from weaning when already growth retarded, they
Figure 3. The hypothalamic-pituitary-thyroid-bone axis. TRH is
synthesized in the hypothalamus and stimulates secretion of TSH
from the anterior pituitary. TSH stimulates the synthesis and
release of thyroid hormones. Thyroid hormones act in bone via
TRa to regulate growth and bone turnover. Thyroid hormones
also act via TRb expressed in hypothalamus and pituitary to inhibit
TRH and TSH synthesis and secretion
Rycina 3. Oś podwzgórze–przysadka–tarczyca–kość. Produko-
wany w podwzgórzu TRH pobudza sekrecję TSH z przedniego
płata przysadki. Z kolei TSH stymuluje syntezę i uwalnianie hor-
monów tarczycy. Hormony te działają na kość poprzez receptory
TRa i regulują wzrost kości i obrót kostny. Hormony tarczycy
hamują ponadto syntezę i wydzielanie TRH i TSH za pośrednic-
twem receptorów TRb zlokalizowanych w podwzgórzu i przysadce
Hypothalamus
Pituitary
Thyroid
Bone
TRb
T4 T3
TRb
TRH
TSH
T4 T3
TRa
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were actually grossly hypothyroid at the critical stage
of thyroid hormone-dependent bone development.
Thus, the phenotype in TSHR knockout mice may re-
flect the effects of severe hypothyroidism followed by
“catch-up” growth and accelerated bone turnover in
response to delayed thyroid hormone replacement [1].
Furthermore, the susceptibility of patients with Graves’
disease to osteoporosis and fracture is not consistent
with the hypothesis that TSH negatively regulates bone
turnover, because the presence of TSHR stimulating
antibodies would be predicted to protect patients from
osteoporosis if TSH is a direct negative regulator of bone
turnover. In addition, two boys treated with thyroid
hormone replacement from birth because of congenital
hypothyroidism due to isolated TSH deficiency had
normal bone mineral density [46].
Overall, these studies suggest that the skeletal ef-
fects of abnormal thyroid status are due primarily to
effects of thyroid hormone deficiency or excess, altho-
ugh direct effects of TSH cannot be excluded as a con-
tributing factor. Unfortunately, resolution of this issue
is problematic. The relative effects of T3 and TSH in bone
cannot be differentiated readily because the HPT axis
maintains thyroid hormones and TSH in a physiologi-
cal reciprocal relationship because of negative feedback
inhibition of TSH by thyroid hormones [1]. Neverthe-
less, studies in mutant mice have enabled this difficulty
to be overcome in vivo.
Figure 4. The relationship between TRa and TRb expression in pituitary and bone determines the
skeletal phenotype of TR knockout mice TRa0/0 and TRb–/–. TRb is predominantly expressed in pituitary
whereas TRa is the main TR expressed in bone. Deletion of TRa does not alter pituitary responsiveness
to T3, so physiological negative feedback inhibition of TSH by thyroid hormones continues normally.
Thus, TRa0/0 mice are euthyroid. By contrast, when TRb is deleted, negative feedback inhibition of TSH
by thyroid hormones is disrupted leading to elevated levels of TSH, T3, and T4 in TRb
–/– mice. The effects of
these mutations in bone result from loss of skeletal TR expression in TRa0/0 mice (skeletal hypothyro-
idism) or from elevated circulating thyroid hormones in TRb–/– mice (skeletal hyperthyroidism)
Rycina 4. Zależność między ekspresją TRa i TRb w przysadce i tkance kostnej determinuje fenotyp
szkieletu u zmutowanych myszy TRa0/0 i TRb–/–. Głównym miejscem ekspresji receptora TRb jest
przysadka, natomiast TRa — kość. Delecja TRa nie powoduje zmiany wrażliwości przysadki na T3,
a zatem fizjologiczny mechanizm zwrotnego hamowania syntezy TSH przez hormony tarczycy nie
ulega zaburzeniu. Co za tym idzie, u myszy TRa0/0 występuje eutyreoza. Z kolei w przypadku delecji
TRb następuje zaburzenie ujemnego sprzężenia zwrotnego między stężeniem hormonów tarczycy
i TSH, co prowadzi do zwiększenia stężeń TSH, T3  i T4 u myszy TRb
–/–. Mutacje te wpływają na
metabolizm kostny: u myszy TRa0/0 brak ekspresji receptora TR w komórkach kości powoduje
hipotyroidyzm kostny, a u myszy TRb–/– dochodzi do wzrostu stężenia krążących hormonów tarczycy
i w rezultacie do hipertyroidyzmu
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Skeletal phenotypes in two contrasting
models of congenital hypothyroidism
Hyt/hyt mice harbour a Pro556Leu mutation in the
TSHR. The mutant receptor does not bind TSH and is
non-functional, resulting in hypoplasia of the thyroid
gland and severe congenital hypothyroidism characte-
rized by a 2000-fold increase in TSH levels in the pre-
sence of barely detectable levels of thyroid hormones
[47]. Pax8 knockout mice lack an essential transcription
factor required for thyroid follicular cell development.
They have also congenital hypothyroidism characteri-
zed by a 2000-fold elevation of TSH and undetectable
thyroid hormone levels, but they possess fully functio-
nal TSH receptors [48]. Thus, both hyt/hyt and Pax8
knockout mice have grossly elevated TSH levels, but in
hyt/hyt mice the TSHR is non-functional whereas in
Pax8 mice it is normal. We reasoned, therefore, that if
TSH exerts a physiologically important role during ske-
letal development and growth then these mice would
display opposite skeletal phenotypes [49]. However,
both mutants had similar skeletal abnormalities consi-
sting of growth retardation, delayed endochondral ossi-
fication, and reduced cortical bone deposition accom-
panied by retention of calcified cartilage in trabecular
bone with impaired remodelling and reduced bone
mineralization. These features are typical of the skele-
tal abnormalities seen in hypothyroidism and occur
despite the divergence in TSH signalling in hyt/hyt and
Pax8 mice, thus demonstrating that during bone deve-
lopment and growth the effects of thyroid hormone
deficiency are independent of TSHR activity [49]. The-
se findings indicate the effects of the HPT axis in bone
are mediated principally by thyroid hormones.
Molecular basis of thyroid hormone
action in bone
In order to investigate the roles of TRa and TRb in ske-
letal development and homeostasis in vivo, mice harbo-
uring mutations or deletions of the Thra and Thrb ge-
nes were characterized. Deletion or mutation of TRa
does not affect circulating thyroid hormone or TSH le-
vels, and mutant mice are consequently euthyroid. Ne-
vertheless, TRa mutants display transient growth re-
tardation, delayed endochondral ossification, and re-
duced bone mineral deposition during growth. In
adults, impaired bone remodelling with reduced bone
resorption results in a marked increase in bone mass,
leading to a phenotype of osteosclerosis, in which bone
mineralization may be normal or increased depending
on the TRa mutation. Thus, mutation of TRa disrupts
T3 action in bone cells in which TRb is predominantly
expressed, resulting in phenotype that recapitulates the
skeletal effects of hypothyroidism [50–53]. By contrast,
mutation or deletion of TRb disrupts the HPT axis, le-
ading to resistance to thyroid hormone characterized
by elevated levels of thyroid hormones and TSH. TRb
mutants display accelerated endochondral ossification
and increased bone mineral deposition during deve-
lopment but have short stature due to premature quie-
scence of the growth plates. In adult TRb mutant or
knockout mice, increased bone turnover with increased
osteoclastic bone resorption results in osteoporosis cha-
racterized by reduced bone mass and low bone mine-
ralization density. Thus, elevated levels of circulating
thyroid hormones in TRb mutant mice activate the re-
maining intact TRa expressed in bone, resulting in phe-
notype that is characteristic of the effects of hyperthy-
roidism in bone [43, 51–53]. Accordingly, analysis of T3
target gene expression in TR mutant mice by in situ hy-
bridization has revealed increased expression in TRb
mutants with elevated thyroid hormone levels but re-
duced expression in TRa mutants despite their circula-
ting euthyroid status [37, 39, 53]. Overall, these findings
demonstrate that thyroid hormones exert anabolic
growth promoting actions during skeletal development
but exert catabolic responses resulting in bone loss in
adults. The differing patterns of expression of TRa and
TRb in the hypothalamus and pituitary and the skele-
ton indicates that the effects of T3 in developing and
adult bone are mediated by TRa [43].
Are the actions of thyroid hormones
in bone direct?
Studies of mice harbouring germline mutations or de-
letions of the Thra or Thrb genes provide compelling
evidence of a key role for TRa in bone, but they cannot
distinguish whether skeletal defects result from the sys-
temic consequences of TR disruption or from local ac-
tions of T3 in skeletal cells. Thus, thyroid hormones re-
gulate activities of numerous signalling pathways that
influence the skeleton including the GH/IGF-1 and sex
steroid axes as well as various growth factors and cyto-
kines that regulate bone cell differentiation and func-
tion. Thus, it is possible that skeletal responses to thy-
roid hormones could be largely secondary to direct ef-
fects of thyroid hormones in non-skeletal cells, or they
could result predominantly from the direct actions of
thyroid hormones in bone cells that could include chon-
drocytes, osteoblasts, osteocytes, and osteoclasts.
In recent studies we investigated expression of the
thyroid hormone transporter MCT8 and the deiodina-
se enzymes in bone cells [54]. MCT8 mRNA was pre-
sent in all bone cell types, and levels of expression did
not differ with cell differentiation. By contrast, the D1
enzyme was not expressed in any bone cell lineage and
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activity of the D2 enzyme was restricted to mature dif-
ferentiated osteoblasts, whilst activity of D3 was pre-
sent in growth plate chondrocytes prior to weaning but
levels declined thereafter and only low levels of D3 were
detected in chondrocytes in older animals. Low levels
of D3 activity were also detected in osteoblasts and oste-
oclasts at all stages of maturation [54]. These findings
support the likelihood that thyroid hormones have im-
portant direct effects in skeletal cells as the activities of
D2 and D3 control T3 availability to the nuclear TR. The
differing patterns of expression of D2 and D3 suggest
that control of T3 availability in chondrocytes during
skeletal development may be dependent on metabolic
clearance by D3, whereas T3 availability to osteoblasts
may be determined by metabolic activation by D2. In
order to test these hypotheses and investigate the role
of thyroid hormone supply to skeletal cells it will be
necessary to characterize the skeletal consequences of
deletion of the Dio2 and Dio3 genes encoding D2 and
D3. Further refinement of our understanding of the
molecular and cellular basis for T3 action in bone will
require cell-specific disruption of thyroid hormone si-
gnalling in bone cells using cre-lox gene targeting tech-
niques in which expression of Cre recombinase in chon-
drocytes, osteoblasts, osteocytes, or osteoclasts will ena-
ble the TRs, deiodinases, and thyroid hormone trans-
porters to be selectively deleted in individual bone cell
lineages. Such approaches will identify which compo-
nents of the thyroid hormone signalling pathway are
responsible for the actions of T3 in specific bone cell ty-
pes. These experiments will provide important and de-
finitive characterization of the molecular mechanism of
thyroid hormone action in bone and will identify novel
drug targets for manipulation of peak bone mass acqu-
isition and bone mineralization.
Summary
— Thyroid hormones are required for growth and es-
tablishment of peak bone mass
— Thyroid hormones are required to maintain optimal
bone strength
— The set-point of the HPT axis may determine frac-
ture risk
— Hypothyroidism and hyperthyroidism are both as-
sociated with increased fracture risk
— Mild degrees of thyroid hormone excess, characte-
rized by suppressed levels of TSH, are associated
with increased fracture risk in post-menopausal
women
— T3-action in bone is mediated by TRa
— T3 has anabolic actions in bone during growth, but
exerts catabolic effects on the adult skeleton
— TSH may also act on bone cells, but independent
opposing effects of T3 and TSH are difficult to reso-
lve because circulating thyroid hormone and TSH
levels are maintained in an inverse relationship by
the HPT axis
— The cellular basis of T3 action in bone is incomplete-
ly understood, and tissue-specific gene targeting will
be required to characterize this in vivo
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